St. Jude Medical Sets New 1-Year High at $71.90 (STJ)
St. Jude Medical (NYSE:STJ)’s share price hit a new 52-week high during mid-day trading on Monday , AnalystRatingsNetwork.com reports. The stock traded as high as $71.90 and last traded at $71.14, with a volume of 2,096,296 shares. The stock had previously closed at $70.13.
STJ has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of St. Jude Medical in a research note on Monday. They now have a $74.00 price target on the stock. Separately, analysts at Wells Fargo & Co. reiterated an “average” rating on shares of St. Jude Medical in a research note on Thursday, May 29th. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of St. Jude Medical in a research note on Friday, May 9th. They now have a $75.00 price target on the stock. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $66.00.
The stock’s 50-day moving average is $66.44 and its 200-day moving average is $64.78. The company has a market cap of $20.146 billion and a price-to-earnings ratio of 27.28.
St. Jude Medical (NYSE:STJ) last posted its quarterly earnings results on Wednesday, April 16th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.01. The company had revenue of $1.36 million for the quarter, compared to the consensus estimate of $1.36 million. During the same quarter in the previous year, the company posted $0.92 earnings per share. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts expect that St. Jude Medical will post $3.99 EPS for the current fiscal year.
St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.